Previously, we discovered that TKI-activated NFκB2 is the key regulator of C-X-C motif chemokine ligand (CXCL)/CXC receptor 2 (CXCR2)-mediated inflammatory pathways in promoting the survival and relapse of FLT3-mut AML blasts ex vivo [9]. The gene discussed is NFKB2; the disease is acute myeloid leukemia.